Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly EBT Margin of 135.29% for Q1 2026, down 2738.0% year-over-year from 5.13% in Q1 2025, and down 130.46% quarter-over-quarter from 58.71% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported EBT Margin for 11 consecutive years, with 135.29% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 2738.0% year-over-year to 135.29%; the TTM figure through Mar 2026 stood at 89.48% (up 249.0% YoY), while the FY2025 annual figure was 83.95%, up 1658.0% from the prior year.
- EBT Margin fell to 135.29% in Q1 2026 per RARE's latest filing, from 58.71% in the prior quarter.
- Across five years, EBT Margin topped out at 58.71% in Q4 2025 and bottomed at 263.3% in Q3 2022.
- Historically, EBT Margin has averaged 132.46% across 5 years, with a median of 135.29% in 2026.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 54750 bps — and 2023, when it surged 10114 bps.
- Ultragenyx Pharmaceutical's EBT Margin stood at 148.32% in 2022, then surged by 32 bps to 100.22% in 2023, then rose by 22 bps to 78.24% in 2024, then rose by 25 bps to 58.71% in 2025, then tumbled by 130 bps to 135.29% in 2026.
- Business Quant data shows RARE's EBT Margin at 135.29% in Q1 2026, 58.71% in Q4 2025, and 112.26% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -42.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.52% |
| Mar 31, 2026 | -135.29% |
| Dec 31, 2025 | -58.71% |
| Sep 30, 2025 | -112.26% |
| Jun 30, 2025 | -68.47% |
| Mar 31, 2025 | -107.91% |
| Dec 31, 2024 | -78.24% |
| Sep 30, 2024 | -95.50% |
| Jun 30, 2024 | -88.92% |
| Mar 31, 2024 | -156.41% |
| Dec 31, 2023 | -100.22% |
| Sep 30, 2023 | -162.16% |
| Jun 30, 2023 | -146.89% |
| Mar 31, 2023 | -162.67% |
| Dec 31, 2022 | -148.32% |
| Sep 30, 2022 | -263.30% |
| Jun 30, 2022 | -176.69% |
| Mar 31, 2022 | -189.86% |
| Dec 31, 2021 | 399.18% |
| Sep 30, 2021 | -89.18% |